Wade T. Johnson

Wade T. Johnson

Auto-generated profile, based on publicly available information

Wade T. Johnson

Department of Chemical and Nano Engineering, University of California, San Diego, La Jolla, CA 92093, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2023 in ACS Nano
Verified
Journal Article
Closed access
WJWade T. Johnson
Wade T. Johnson
DMDavid McBride
David McBride
MKMatthew Kerr
Matthew Kerr
ANAnders Nguyen
Anders Nguyen
MZMartina Zoccheddu
Martina Zoccheddu
NSNisarg J. Shah
Nisarg J. Shah

5 September 2025 in Science Advances
Verified
Journal Article
Open access
SYShen Yang
Shen Yang
ESEugenio Santelli
Eugenio Santelli
CGCarlos G. Gonzalez
Carlos G. Gonzalez
WJWade T. Johnson
Wade T. Johnson
ICIrene V. Choi
Irene V. Choi
NBNunzio Bottini
Nunzio Bottini
Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) is encoded by a gene strongly associated with lupus and other autoimmune diseases. PTPN22 regulates T cell receptor (TCR) signaling through dephosphorylation of the kinases lymphocyte-specific protein tyrosine kinase (LCK) and zeta-chain–associated protein kinase 70 (ZAP70). The regulation of PTPN22 remains poorly understood. Here, we identify PTPN22 Ser 449 as a protein kinase A phosphorylation site, which is triggered by TCR engagement and is hyperphosphorylated in lupus peripheral blood cells. PTPN22 Ser 449 phosphorylation selectively lowered the affinity of PTPN22 for ZAP70 versus LCK but also indirectly suppressed inhibitory LCK Tyr 192 phosphorylation through a ZAP70-CD45 signaling axis. The resulting dephosphorylation of LCK Tyr 192 not only enhanced TCR signaling but also modulated pathway activation downstream the TCR. In vivo loss of PTPN22 Ser 449 phosphorylation reduced T cell responses and suppressed experimental lupus nephritis. These results suggest that PTPN22 Ser 449 phosphorylation promotes a CD45-mediated retrograde ZAP70-LCK feedback loop that enhances T cell responses and promotes autoimmunity.

6 August 2025 in ACS Central Science
Verified
Journal Article
Open access
WJWade T. Johnson
Wade T. Johnson
EWElizabeth L. Wilkinson
Elizabeth L. Wilkinson
NINeha Iyer
Neha Iyer
MDMaksim Dolmat
Maksim Dolmat
MBMiriam Bollmann
Miriam Bollmann
NSNisarg J. Shah
Nisarg J. Shah
Disease-modifying antirheumatic drugs (DMARDs) have greatly improved the treatment of rheumatoid arthritis (RA), but strategies to prevent disease onset and recurring flares remain limited. While abatacept (CTLA-4 IgG) can delay RA onset and corticosteroids are used for flare control, the benefit is temporary. We report that combining standard-of-care treatments with a locally administered immunomodulatory agent, termed Agg-CLNP, enhances both disease prevention and flare mitigation. Agg-CLNP consists of polymer nanoparticles conjugated with an immunodominant aggrecan peptide and encapsulate calcitriol. These nanoparticles are optimized for uptake by dendritic cells (DC) in lymph nodes proximal to arthritic joints. In vitro, Agg-CLNP suppressed costimulatory molecules and HLA class II (HLA-2) expression and upregulated CTLA-4 in human monocyte-derived DC from healthy and RA donors. In SKG mice, a T cell-driven RA model, Agg-CLNP combined with CTLA-4 IgG synergistically delayed disease onset and reduced severity. In a dexamethasone (Dex) withdrawal flare model, post-Dex Agg-CLNP treatment reduced flare severity and preserved a regulatory phenotype in DC, while suppressing local pathogenic TH17 cells. Next generation RNA sequencing of lymph node DC revealed Ctla4 upregulation and changes in other immunomodulatory genes linked to flare prevention. These findings highlight Agg-CLNP as a potential therapeutic strategy to address critical unmet needs in RA management.